Chapter 33: Antifungal Drugs

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Okay, let's unpack this.

Imagine you are like a police negotiator dealing with a tense hostage situation.

Oh, what?

Now, if the bad guys are all wearing bright red ski masks, your job is, you know, relatively straightforward.

Right.

Yeah, you can easily tell the criminals apart from the innocent hostages.

Exactly.

You just send in a tactical team, they target the red masks, the hostages are saved and collateral damage is minimal.

Which is the dream scenario.

Yeah.

And that is essentially what it's like treating a bacterial infection like strep throat with a standard antibiotic.

It's clean.

It's targeted.

Right.

Because bacteria are structurally completely different from our own human cells.

They have different cell walls, different machinery.

So the antibiotic spots those obvious differences, red ski masks and attacks, without really bothering the patient cells too much.

But today we are pulling from a stack of pharmacology research, specifically focusing entirely on Chapter 33, Antifungal Drugs, from Lippenpot Illustrated Reviews.

It's a dense chapter.

It really is.

And diving into this material, you quickly realize that treating a fungal infection of mycosis is a totally different kind of hostage negotiation.

Oh, absolutely.

In this scenario, the bad guys aren't wearing ski masks, they are wearing the exact same clothes as the hostages.

Which just makes it incredibly complicated.

And the reason for this really comes down to one foundational biological fact.

Okay.

Unlike bacteria,

fungi are eukaryotic.

Meaning their cellular structure and their metabolic pathways are like remarkably similar to ours.

Because mammalian cells are also eukaryotic.

Exactly.

So if you just carpet bond the area with a drug designed to kill eukaryotic cells, you aren't just killing the fungus, you're killing the patient.

Right.

Finding a chemical weapon that selectively targets the fungal invader while leaving the human host intact is, well, it's one of the toughest challenges in modern medicine.

Because of that shared biology.

Yeah.

Because of it, fungi just laugh at standard antibacterial antibiotics.

Like penicillin won't do a thing.

We need highly specialized tools that hunt for these microscopic needle and haystack differences.

And understanding those tiny differences is the whole mission of our deep dive today.

We're going to translate all this dense drug info into plain language.

Sounds good.

We're going to look at how these antifungal drugs work, why they cause the wild side effects they do, and the intense evolutionary arms race happening right now.

It's fascinating stuff.

But before we get to the weapons, let's look at the targets.

Even though fungi are eukaryotic, they do have a unique armor system, don't they?

They do.

Fungi essentially build themselves a heavily fortified house.

Okay.

I like that analogy.

Yeah.

So looking at figure 33 .3 in the text, the first layer of defense, the outer brick wall, is the fungal cell wall.

Right.

Now, plants have cell walls made of cellulose and bacteria use peptidogen kinase.

But fungi construct an exceptionally rigid wall out of a tough carbohydrate called chitin.

Chitin.

Wait, that's the same stuff that makes up the exoskeletons of crabs and beetles, right?

The very same.

It's incredibly tough.

Wow.

Now, just inside that chitin brick wall is the insulation of the house,

the plasma membrane.

Okay.

Human cell membranes use cholesterol to stay flexible and stable.

But fungi don't use cholesterol.

They use a slightly different unique lipid molecule called ergosterol.

Okay.

So chitin and ergosterol, those are the two major deviations.

That's the chink in the armor we have to exploit.

Precisely.

If we can target those specific building blocks, we can theoretically kill the fungus and spare the patient.

And we desperately need to exploit them because opportunistic fungal infections have been steadily rising over the last few decades.

Yeah.

And what's fascinating here is that this rise is actually like a side effect of the triumphs of modern medicine.

Because we have a growing population of people living with chronic immune suppression, patients undergoing organ transplants or fighting through cancer chemotherapy or managing HIV.

We are saving lives, but we are simultaneously creating an environment where these fungi can suddenly thrive and turn deadly.

Fungi that normally wouldn't stand a chance against a healthy immune system.

Yeah.

And figure 33 .2 actually breaks these pathogens down into yeasts like candida and molds like aspergillus and dimorphic fungi.

So when a patient with a compromised immune system develops a severe, life -threatening systemic fungal infection,

doctors usually reach for the heaviest hitter first, right?

Yeah.

A drug called amphotericin B.

Looking at the pharmacological data, amphotericin B is a force of nature, but the mechanism of action is intense.

Oh, it really is.

It directly attacks that unique ergosterol we just talked about in the plasma membrane.

Okay.

So it goes right for the insulation.

Yeah.

It binds hydrophobically to the ergosterol and then the drug molecules basically gang up.

They assemble themselves together and embed right into the lipid bilayer of the fungal cell, forming a literal pore.

A physical hole in the cell membrane?

You can actually see it illustrated perfectly in figure 33 .4.

It literally punches holes in the fortification.

Wow.

And the therapeutic effect of this is devastating for the fungus because, you know, a cell is essentially a carefully balanced bag of water and electrolytes.

Right.

Once amphotericin B punches those pores,

vital electrolytes, particularly potassium, start leaking right out of the cell.

And without that potassium maintaining the electrical gradients, the cellular machinery just shuts down and the fungus dies.

Exactly.

It is a highly effective killer.

But here is where I get caught up on this.

We established that fungi and human cells are both eukaryotic.

Right.

We don't have ergosterol, but we do have cholesterol, which is structurally pretty similar.

Doesn't this whole punching drug get confused?

It absolutely gets confused.

Amphotericin B has a very low therapeutic index, meaning the dose required to kill the fungus is uncomfortably close to the dose that harms the patient.

Yikes.

Yeah.

It is notoriously toxic because it does inadvertently bind to human cholesterol, especially in the kidneys.

And the adverse effects listed in figure 33 .6 are terrifying.

First, you get the immediate infusion reactions.

Right.

The shake and bake.

Yeah.

Patients often develop severe fever and chills about one to three hours after the IV starts.

That's just the immune system reacting to the drug and the rapid breakdown of fungal cells.

But the long -term danger is the kidney failure.

Okay.

Even though very little of the drug is actually excreted in the urine, it causes a serious decrease in the kidney's filtration rate.

Oh, wow.

The patient's serum creatinine spikes and they start leaking their own potassium and magnesium, just like the fungal cells do.

Plus it can trigger a shock -like drop in blood pressure and severe anemia.

So wait, if this drug is essentially a chemical wrecking ball that damages the kidneys, how do we safely administer it?

Well, the clinical workarounds are a huge part of managing this therapy.

Okay.

To handle the fever and chills, doctors will often pre -medicate the patient with a corticosteroid or an antipyretic, something like acetaminophen, before starting the IV.

Oh, that makes sense.

And to mitigate the severe kidney damage, they use a technique called sodium loading.

They infuse normal saline into the patient prior to giving the drug, which helps protect the delicate tubules in the kidneys.

The text also mentions liposomal formulations.

What does that mean?

That is a brilliant piece of biochemical engineering.

Basically, they package the toxic amphotericin B inside artificial lipid bubbles liposomes.

Okay.

This keeps the drug sequestered while it circulates in the human bloodstream, preventing it from attacking human kidneys.

Oh, so it hides the drug.

Exactly.

The bubble only breaks open and releases the drug when it physically binds to the fungal cell wall.

It significantly reduces the toxicity,

but those formulations are astronomically expensive.

Okay, so amphotericin B is our brute force option.

It punches holes in the wall.

But since we have these holes, what if we use another drug that can slip right through them and attack the cell from the inside?

Now you're thinking.

That brings us to a drug called flucitacin, often abbreviated as 5 -FC.

It relies entirely on a Trojan horse approach.

This mechanism is wild.

Flucitacin approaches the fungal cell, but it can't just diffuse inside, it has to be invited in.

Right.

And the fungal cell has a specific transport enzyme on its surface called cytosine -specific permease.

Which is key because mammalian cells do not have this enzyme at all.

Figure 33 .7 shows this so clearly.

So the fungus actively pulls the drug inside, thinking it's a nutrient, while human cells just ignore it.

But once it's inside the fungal cell, the trap is sprung.

The fungus' own internal enzymes mistakenly metabolize this harmless -looking clucitazine into a highly toxic compound called 5 -fluoracil, or 5 -FU.

Wait, 5 -FU, if that name sounds familiar, it's because that's a potent chemotherapy drug, right?

Exactly.

Basically it gets incorporated right into the cell's RNA and DNA, fundamentally short -circuiting protein synthesis and stopping cellular replication dead in its tracks.

And here is where the synergy happens, remember amphotericin B punching those holes.

When doctors use amphotericin B and flucitacin together, the amphotericin increases the permeability of the fungal cell, allowing massive amounts of the flucitacin Trojan horse to flood in.

And that combination is absolutely necessary.

You might wonder, you know, if flucitacin is so clever, why not just use it by itself and spare the patient the kidney toxicity of amphotericin?

Yeah, why not?

The answer is rapid resistance.

Fungi are incredibly adaptable.

If you use flucitacin alone, the fungal population will quickly mutate.

Oh, so they just change the locks.

Exactly.

They alter their transport enzymes so they stop pulling the drug inside, or they mutate the internal enzymes that convert it to the toxic 5 -FU.

Used alone, it becomes useless almost immediately.

But combined, it's a powerful tool for serious infections like Cryptococcal meningitis.

Absolutely.

But the Trojan horse isn't perfect, it has some friendly fire.

The adverse effects include dose -related reversible bone marrow depression.

The pharmacology notes highlight neutropenia, which is a dangerous drop in the white blood cells that fight off other infections and thrombocytopenia, meaning you lose the platelets necessary to clot blood.

And it also causes severe intestinal issues like enterocolitis.

And the reason for that gut toxicity is fascinating to me.

Oh, it really is.

Even though human cells don't have the enzyme to pull flucitacin inside, the bacteria living in our own intestinal microbiome do possess enzymes that can convert some of the drug into that toxic 5 -FU chemotherapy agent right in our gut.

Wow, so the collateral damage is actually caused by our own gut bacteria betraying us.

Yeah, pretty much.

Okay, so the brute force hole punching is highly toxic.

The Trojan horse causes friendly fire.

What is Plan C?

Plan C.

Yeah, if ergosterols is the key structural weak point, instead of waiting for the fungus to build the wall and then punching holes in it, why don't we just stop the fungus from manufacturing ergosterol in the first place?

Cut off the supply chain.

That is the exact strategy of the biggest class of antifungal drugs, the azoles.

This includes topical imidazoles for surface infections and systemic triazoles for deep infections.

Let's focus on the systemic ones.

Figure 33 .8 shows how the mechanism here targets the assembly line.

Right, the azoles inhibit a very specific fungal enzyme called 14 -alpha dimethylase.

Got it.

Normally, this enzyme takes a precursor molecule called lanosterol and converts it into the final product, ergosterol.

The azoles basically throw a wrench into that enzyme.

So without ergosterol, the fungal membrane becomes unstable, leaky, and cellular growth just halts.

Exactly.

It's a fungistatic effect, meaning it stops the fungus from growing and replicating, giving the patient's immune system a chance to sweep in and clear the infection.

But if we connect this to the bigger picture, there's a massive pharmacological complication.

Oh, huge.

Right, because I thought we were targeting a fungal enzyme.

Why do the clinical warnings in, like, figures 33 .9 and 33 .11 spend so much time talking about the human liver?

Because of evolutionary overlap.

That fungal 14 -alpha dimethylase enzyme,

it belongs to a massive family of enzymes known as cytochrome P450.

Yeah.

Now, humans also rely heavily on cytochrome P450 enzymes.

Specifically,

an isoenzyme in our liver called CYP3A4.

And that's the one responsible for metabolizing and clearing out, what, roughly half of all the medications on the market?

Basically, yeah.

And the azoles aren't perfectly selective.

They don't just block the fungal CYP450, they inadvertently block human hepatic CYP452.

Wow.

So they essentially shut down the liver's drug clearing machinery.

Which creates a logistical nightmare for a doctor.

If you have an immunocompromised patient, they are likely already taking a cocktail of medications, statins for their heart,

warfarin to thin their blood, or immunosuppressants for a transplanted organ.

If you add an azole to treat a fungal infection, the liver stops breaking down those other

Their concentrations in the blood will dangerously skyrocket, leading to severe toxicity or bleeding.

So doctors have to be incredibly careful, constantly adjusting dosages, and they have to choose the right azole for the job, because they all behave very differently in the body.

Yeah, if you look at the major options moving through the chapter, it's a real puzzle.

Let's run through the lineup.

If a patient comes in with a straightforward yeast infection, or maybe cryptococcal meningitis, what's the go -to?

Usually fluconazole.

It's highly active against many candida species.

It absorbs wonderfully when taken orally, and it easily crosses into the cerebrospinal fluid to protect the brain.

Plus, uniquely among the azoles, the vast majority of fluconazole is excreted completely unchanged in the urine.

So instead of stressing the liver, you just have to watch out if the patient has core kidney function.

But it has a blind spot.

It is totally useless against aspergillus molds.

True.

So what if the patient is infected with a dimorphic fungus, like histoplasmosis, from breathing in spores?

Then you might pivot to a draconazole, which has a much broader spectrum.

But a draconazole is notoriously finicky.

How so?

Well, if you give the patient the capsule form, they absolutely must take it with a full meal and an acidic beverage like a cola just to get it to absorb into the bloodstream.

Wait, really?

With a soda?

Yeah.

But if you have prescribed the liquid oral solution, they have to take it on a strictly empty stomach.

That is bizarre.

And the study questions highlight a massive red flag with itchaconazole.

It has a negative inotropic effect.

Inotropic refers to the force of muscle contractions.

A negative inotropic effect means the drug actually weakens the physical squeezing force of the heart muscle.

Wow.

Because of this, it must be strictly avoided in patients with a history of ventricular dysfunction, like heart failure.

You don't want to weaken a heart that is already struggling to pump.

Okay.

So what if the patient is severely immunocompromised, say, recovering from leukemia and needs heavy duty prophylaxis to prevent mold infections before they even start?

Doctors often use posichonazole.

Structurally, it's a lot like itchaconazole, but it has a fascinating metabolic quirk.

Most azoles are processed by those CYP450 enzymes in the liver.

Posichonazole bypasses that system almost entirely.

Oh, nice.

It is eliminated through a process called glucuronidation, where the body essentially slaps a sugar molecule onto the drug to make it water soluble so it can be excreted.

Hold on.

If it isn't metabolized by the CYP450 system, does that mean we don't have to worry about those dangerous drug interactions?

Unfortunately, no.

Even though the CYP450 system isn't breaking down the posichonazole, the drug still actively inhibits the CYP3A4 enzymes.

Ah, of course.

Yeah.

So those massive drug interactions are still a very real threat.

Oh, and patients need to avoid stomach acid reducers like PPIs with this one, too.

It never makes it easy.

Now what if the patient already has a confirmed invasive aspergillus infection?

We know fluconazole won't work.

The modern drug of choice for invasive aspergillosis is voriconazole.

It's incredibly effective and has largely replaced the highly toxic amphotericin B for this specific mold.

Okay.

But voriconazole has what pharmacologists call non -linear pharmacokinetics.

Which means it doesn't behave predictably.

With most drugs, if you double the dose, the amount in your blood doubles.

Right.

But with voriconazole, the liver enzymes that process it specifically, one called CYP2C19, can get saturated or maxed out.

Right.

And to make matters worse, human genetics vary wildly when it comes to CYP2C19.

Some people are rapid metabolizers, and some are very slow.

Okay, so if a patient is a slow metabolizer, those liver enzymes hit their absolute limit.

Suddenly, instead of a steady decline, the concentration of the drug in the blood spikes exponentially.

And when voriconazole builds up to those high trough concentrations, the side effects are wild.

It readily crosses the blood -brain barrier, and patients experience profound neurotoxicity.

Wait, like what?

We're talking intense visual and auditory hallucinations.

They start seeing shifting colors and hearing things that aren't there purely because their liver enzymes got overwhelmed.

That is terrifying.

Which is exactly why doctors have to constantly draw blood and monitor the exact therapeutic levels of voriconazole in a patient.

It's a very tight, tight rope to walk.

Finally, in the systemic azole class, we have isovuconazole, which is actually administered as a pro -drug.

Meaning, the chemical in the IV bag is technically inactive.

Once it hits the patient's bloodstream,

enzymes in the blood rapidly hydrolyze it, clipping off a piece of the molecule to activate the drug.

Exactly.

It's broad spectrum, similar to voriconazole, but generally has a slightly cleaner side effect profile.

So what does this all mean?

Figure 33 .Meo synthesizes all this nicely, comparing the half -lives, the roots, and the different CYP enzyme inhibitions among these complex drugs.

It's a great summary chart.

So we have punched holes in the membrane, we've sabotaged the DNA, and we've starved them of ergosterol.

But what about that cheatin' brick wall we discussed at the very beginning?

Right.

For that, we bring in the kind of candins.

Drugs like caspofungin, mecafungin, and anectilofungin.

These are the wallbreakers.

Okay.

They interfere directly with the physical synthesis of the fungal cell wall.

Specifically, they inhibit the production of beta -1 -3 -D -glucocan, which acts like the mortar holding the chidin bricks together.

So without that structural integrity, the cell wall literally bursts open at leases and the fungal cell dies.

Exactly.

They're incredibly potent, especially against aspergillus and candida strains that have mutated and been resistant to the ozoles.

But the biggest relief with the echinocandins is what they don't do.

Right.

This raises an important question regarding drug interactions.

We just spent a long time untangling the nightmare of CYP450 interactions with the ozoles.

The echinocandins, particularly mecafungin and anctilofungin, are not substrates for CYP450 enzymes.

Oh, that is huge.

So they don't interact with the liver's drug clearing machinery at all?

Practically not at all.

Which means if you have an ICU patient on a dozen different heart and blood pressure medications, you can administer an echinocandin with virtually no fear of drug interactions.

Wow.

A massive clinical advantage.

They do have some administration quirks though, right?

They do.

They are IV only and you have to infuse them very slowly over an hour.

Why is that?

Because if a nurse pushes the IV too quickly, the rapid breakdown of the fungal walls triggers a massive histamine -like release in the patient, causing severe facial flushing and a drop in blood pressure.

Oh, wow.

And caspofungin uniquely requires a heavy -loading dose on the first day.

And doctors have to avoid giving it, alongside cyclosporine, a common anti -rejection drug because the combination can stress the liver.

Correct.

Now up to this point, we've been dealing with systemic, life -threatening infections.

But we have to address the superficial, frustrating infections that plague the outer layers of the epidermis, the nails, and the hair.

The cutaneous mycotic infections.

Yes, the dermatophytes.

And let's clear up a major myth right now.

These common skin infections are almost always colloquially called ringworm because they leave red, scaly, ring -like patches on the skin.

Right.

But there is absolutely no worm involved.

It is a mold -like fungus officially called tinea.

To fight these surface invaders, we use drugs that, again, target ergosterol, but they intercept the assembly line at a much earlier stage than the azoles.

The primary class here, shown in figure 33 .12, are the squalene epoxidase inhibitors.

And the standout oral drug in this class is turbinifine.

OK, looking at the pathway, by inhibiting the enzyme squalene epoxidase, turbinifine pulls off a devastating two -for -one attack.

Yes it does.

First, it stops the production line, starving the cell of the ergosterol it needs for its membrane.

Right.

But second, because the assembly line is blocked early, the raw precursor molecule squalene starts piling up inside the cell.

And high levels of squalene are incredibly toxic to the fungus.

So you starve the cell and poison it from the inside simultaneously.

Exactly.

And turbinifine has a highly unusual pharmacokinetic profile that makes it the absolute gold standard for treating onychomycosis, which are deep fungal infections of the nail beds.

The way it moves through the body, detailed in figure 33 .13, is wild.

Once absorbed, it binds heavily to plasma proteins and actively deposits itself directly into the skin, the nails, and adipose or fat tissue.

Because it gets physically trapped in these slow -moving tissues, it doesn't get cleared by the kidneys quickly.

It has a massive terminal half -life of 200 to 400 hours.

It acts like a slow -release capsule embedded right at the site of the infection.

That lingering effect is why it is so successful at clearing stubborn nail infections, though the patient still has to take the pills for about three months while the healthy nail grows out.

Wow.

Now, before turbinifine came along, the old standard was a drug called grizofulvin, but the mechanism is totally different.

Figure 33 .14 shows how it physically disrupts the fungal mitotic spindle.

The mitotic spindle.

It's basically the network of microscopic cables that pull a cell apart when it's trying to divide and replicate.

Grizofulvin essentially gums up the works of those cables.

It stops the cells from dividing, but it doesn't immediately kill them.

It just holds them in stasis and relies heavily on the slow, natural shedding of human skin and nails to physically push the infection out of the body.

Exactly.

Because of this, treating a toenail infection with grizofulvin could take up to a full year of daily medication.

A year?

Yeah.

Plus, it requires a high -fat meal just to absorb into the blood.

And crucially, whereas the azoles inhibit the liver's CYP450 enzymes, grizofulvin actually induces them.

Yes.

It kicks the liver into overdrive, which speeds up the metabolism of other drugs, meaning things like blood thinners might suddenly stop working because the body clears them out too fast.

Wow.

Because of the long treatment times and these interactions, it makes sense that turbinifine has largely replaced it.

Absolutely.

And finally, we have the totical special forces.

For eukosal infections like oral thrush, we have nystatin.

Oh, nystatin.

It's a polyene, exactly like amphotericin B, meaning it punches holes in the membrane.

Right.

But it is way too toxic to ever inject into a human vein.

So it's strictly used as a topical cream or a swish -and -swallow liquid that just passes right through the digestive tract without absorbing.

Makes sense.

You also have your topical imidazoles, like clotrimazole and myconazole, which are the over -the -counter creams you grab for athlete's foot or local yeast infections.

And a few really unique chemical operators.

Sacloperox acts as a supply chain disruptor, hoarding essential elements so the fungus can't synthesize RNA.

And tavabrol specifically intercepts the blueprints, blocking fungal protein synthesis by inhibiting a tRNA synthetase.

Yeah.

And then tolentate literally physically deforms the fungus, distorting its microscopic branches, the hyphae so it looks like a crumpled straw and can't grow.

Though surprisingly, it is completely ineffective against Candida yeast.

Stepping back and looking at this entire arsenal from the chapter, the progression of logic is what really stands out to me.

It's beautifully systematic.

Right.

We started at the outermost fortifications, the cell wall, and shattered it with echinocandins.

We moved to the plasma membrane, punching holes with amphotericin B.

We systematically dismantled the ergosterol assembly line, blocking it late with the azoles and early with turbinifine.

And we slipped right past the gates with the flucidacy and trojan horse to sabotage the DNA from the inside.

It just proves that knowing the specific foundational physiology of the pathogen perfectly predicts how the pharmacology of the drug will work.

And understanding that pharmacology explains exactly why a patient might suffer from kidney damage or experience a hallucination or require a specific dosage adjustment.

Exactly.

But the text leaves us with one incredibly provocative thought to mull over.

This isn't a static, hostage situation.

It is an active, ongoing evolutionary arms race.

We've spent this whole time talking about how cleverly we've engineered these drugs to target the fungi.

But the fungi are engineering right back.

They're actively mutating the genetic codes for their 14 -alpha dimethylase enzymes so that our azole drugs physically can't bind to them anymore.

Even more incredibly, some strains are developing biological efflux pumps.

Wait, efflux pumps?

Like, they are literally building microscopic sump pumps into their membranes.

Yeah, exactly.

To recognize their drugs and spit them right back out of the cell before they can cause any damage.

They are constantly reinforcing the fortress.

As precise as our pharmacology is, the biological adaptability of these pathogens is just as sophisticated.

It really makes you wonder.

You know, we've mapped their defenses and built incredible chemical weapons to breach them.

But as they keep mutating, building pumps, and changing the locks,

who is going to win the next phase of this microscopic war?

It's a scary thought.

It really is.

Thank you for joining us on this deep dive, and a warm thank you from the Last Minute Lecture Team for making us part of your study routine.